24 Hours of Stem Cells

Over the past eight years, we have hosted over 300 leading scientific presentations at the Gibco virtual stem cell event–now 5 Days of Stem Cells. Below is a complete list of presentations and speakers since 2013 with select presentations available*.

Share your research with 3,000+ researchers worldwide!

If you'd like to share your latest discoveries at this renowned virtual stem cell conference, contact the event coordinator at chelsie.wajda@thermofisher.com.


Presentation Speaker Affiliation
Rotea: A versatile cell therapy workflow instrument for cell isolation, washing, and concentration Carl Dargitz Thermo Fisher Scientific
Development of a robust and scalable culture platform for expansion and neural induction of human pluripotent stem cells in suspension culture Cláudia Miranda Institute for Bioengineering and Biosciences (iBB), University of Lisbon
Differentiation of iPSCs in 3D: Leveraging suspension cultures for scale and efficiency David Kuninger Thermo Fisher Scientific
Optimization and standardization in stem cell manufacturing for the fight against COVID-19 Donna Chang Hope Biosciences
Using iPS-derived cells to generate a functional human liver through 3D bioprinting Ernesto Goulart Center for the Study of Human Genome and Stem Cells – University of Sao Paulo
Advancing pluripotent stem cell technologies for research and therapy of blood diseases Igor Slukvin University of Wisconsin
Human iPSC-derived vascularised and innervated cardiac organoids for modelling heart diseases in a dish Jarmon Lees St Vincent's Institute of Medical Research
A high-throughput functional screen reveals human embryonic stem cell self-renewal signals Jean Lu Genomics Research Center, Academia Sinica
Insulin-Producing Islets to Combat Diabetes from Stem Cells Jeff Millman Washington University School of Medicine
iPSC-based high throughout platforms for screening novel therapeautics for treatment of Alzheimer's Disease and Parkinson's Disease Jiayin Yang Cell Inspire Therapeutics
Personalized cell therapy for Parkinson’s disease Kwang-Soo Kim McLean Hospital/Harvard Medical School
Using stem cells in cartilage repair and tissue engineering Laila Montaser Medicine Menoufia University, Egypt
In vitro models of human neurogenesis Larisa Haupt  Queensland University of Technology 
A human stem cell based model for retinoblastoma Laura Steenpass Technical University Braunschweig
Advanced tools for knock-in genome editing in iPSCs Matt Poling  Thermo Fisher Scientific
Addressing the needs of 3D suspension culture systems through the optimization of a new PSC medium Michael Akenhead Thermo Fisher Scientific
Characterization of human iPSC-derived neurons by transcriptomics and proteomics for drug discovery Naomi Okugawa & Dirk Walther Biogen
New enabling technologies for 3D quantitative cellular biology using High-Content Screening Nick Radio Thermo Fisher Scientific
Optimizing stem cells workflows to build better disease models Omar Farah Thermo Fisher Scientific
Tackling Glioblastoma with organoid models Richa Singhania Weill Cornell Medical Center 
Epigenetic regulation of human naïve pluripotency Ritu Kumar Weill Cornell Medicine
Transitioning from discovery and development to manufacturing - Challenges and opportunities Rupa Pike Thermo Fisher Scientific
Adipose-derived stem cells for skin regeneration Silvia E. Castro Piedra & Johan Morales Sanchez Biotechnology Research Center, Costa Rica Institute of Technology
Human stem cell derived cardiomyocytes for healthcare translation: compound screening and tissue engineering Soong Poh Loong National University of Singapore Ternion Biosciences        
Modelling disorders of the brain through patient-derived stem cells Thomas Durcan MNI, McGill University
Understanding human pluripotent states and their applications Thor Theunissen  Washington University School of Medicine
Human iPSC-based disease modeling and therapeutic development Yanhong Shi  City of Hope
Molecular dynamics associated with development of human GABAergic interneurons Zhexing Wen Emory University School of Medicine


Presentation Speaker Affiliation
Turning human pluripotent stem cells into highly-pure and engraftable tissue progenitors Lay Teng Ang Stanford University School of Medicine
Survival of the Fittest: The Cause and Consequences of Genetic Changes in Human Pluripotent Stem Cells Ivana Barbaric University of Sheffield
CTS StemPro HSC Expansion Medium for Cell and Gene Therapies Abigail Becker Thermo Fisher Scientific
Parkinson’s Disease in a Petri Dish: Harnessing iPSCs to develop an improved model of Personalized Medicine Indrani Datta National Institute of Mental Health and Neuro Sciences
Organoids, Spheroids, and 3D Cell Culture Models, Oh My!: Using advanced cell culture models, tissue clearing, and high content confocal microscopy to get the most of your in vitro studies Erin Edwards Visikol, Inc.
Manufacturing pluripotent cell therapeutics: the importance of quality from the very beginning Ben Fryer Pluristyx, Inc.
3D Neural Organoid Formation from iPSCs Edwin Golez Thermo Fisher Scientific
Cancer Spheroid Formation Using Nunclon Sphera Microplates Edwin Golez Thermo Fisher Scientific
GMP Ancillary Materials for Cell and Gene Therapy Manufacturing: What to consider and when to make the switch Kasey Kime & Eric Roos  Thermo Fisher Scientific
Designing the genome editing strategies for stem cells Sanjay Kumar Thermo Fisher Scientific
Characterization assays for human iPSC Rex Lacambacal Thermo Fisher Scientific
Circulating Mesenchymal Stem Cells in Bone Healing Gang Li The Chinese University of Hong Kong
The basics of stem cell biology and a spot light on perinatal stem cells Rebecca Lim Monash University
Focus on stem cell quality: Improving rigor and reproducibility through characterization Tennielle Ludwig & Erik McIntire WiCell Research Institute
iPSC Generation, Culture and Banking in 2019: What do I need to know to start my iPSC project today Gustavo Mostoslavsky Boston University School of Medicine
Characterization of multiple phenotypes in individuals with idiopathic autism using high-throughput screening of hiPSC-derived cortical organoids Michael Nestor Hussman Institute for Autism
Using iPSCs and Cerebral organoids to dissect the pathophysiology of brain growth disorders Filomena Pirozzi Seattle's Children Research Institute
Gene editing in hematopoietic stem cells: tools for tracking, studying gene function, disease modeling, and potential promise for gene therapy Jason Potter Thermo Fisher Scientific
Human Pluripotent Stem Cells-Derived 3D Hepatospheres Hassan Rashidi UCL Great Ormond Street Institute of Child Health
Characterization of Independent Clones of Human Induced Pluripotent Stem Cell-line-NCCSi005 derived from Control Individual of Indian Ethnicity Anjali Shiras  National Centre for Cell Science, Pune
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer Hervé Tiriac  University of California - San Diego
Single Cell Sorting of Genome Edited iPSC Cell Pools Garrett Wong Thermo Fisher Scientific
Exosomes and beyond: translation of small molecules and cellular organelles Phil Yang Stanford University School of Medicine
Using human pluripotent stem cells as platform for studying diseases and drug discovery Ting Zhou  Memorial Sloan Kettering  


Presentation Speaker Affiliation
Efficient generation of pancreatic β cell precursors from human pluripotent stem cells Essam Abdelalim Diabetes Research Center - QBRI College of Science and Engineering, HBKU
GMP Ancillary Materials for Cell and Gene Therapy Manufacturing: What to consider and when to make the switch Joanna Asprer
Lauren Sangenario
Thermo Fisher Scientific
Thermo Scientific Cell Locker System Segregates Stem Cells, Protecting from Contamination and Enhancing Environmental Stability MaryKay Bates Thermo Fisher Scientific
Autologous iPS Cell Therapy for Macular Degeneration: From Bench-To-Bedside  Kapil Bharti National Eye Institute National Center for Advancing Translational Sciences, National Institutes of Health
Strategies for Successful Grant Proposals Devon Brewer Science Docs
Embryonic Stem (ES) Cell FBS Qualified Carl Dargitz Thermo Fisher Scientific
Pluripotent stem cell picking Carl Dargitz Thermo Fisher Scientific
Differentiating neurons Jordan Dizon Thermo Fisher Scientific
Biotechnology Entrepreneurship  Phil Greenwood University of Wisconsin-Madison
Undiagnosed disease to rare disease discovery: Perspectives from a patient family Gay Grossman ADCY5.org
Human PSC-based disease modeling to study X-linked Dystonia-Parkinsonism William Hendriks Harvard Medical School
Dept. of Neurology, Mass Gen Hospital
Generation and application of 3D-organoid cell culture models using human induced pluripotent stem cells (iPSCs) for drug discovery Ryan Hicks** AstraZeneca
Improved Neuronal Performance with the Gibco B-27 Plus Culture System David Kuninger Thermo Fisher Scientific
Build Your Personal Brand Joe LaPointe Thermo Fisher Scientific
Molecular methods to QC cells intended for translation Jeanne Loring The Scripps Research Institute
Routine passaging Chad MacArthur Thermo Fisher Scientific
Towards commercial manufacture of pluripotent stem cell derived therapies Rhys Macown** Cell and Gene Therapy Catapult
Disease modelling with human pluripotent stem cells: general principles and specific applications to obesity variants in human pluripotent stem cells Florian Merkle University of Cambridge
Applications of Brain-Model Technology Alysson Muotri** University of California, San Diego
Human stem cells for modelling neurological disease and its therapeutic applications Rakhi Pal Centre for Brain development and Repair, Instem, Bangalore
Beyond Automated iPSC reprogramming: applications for a fully automated cell culture system for pluripotent stem cell research Daniel Paull The New York Stem Cell Foundation Research Institute
Reprogrammed stem cells to study psychedelic substances Stevens Rehen D'Or Institute for Research and Education (IDOR) & Institute of Biomedical Sciences Federal University of Rio de Janeiro
Use of stem-cell derived endothelial cells for disease relevant cell modeling and drug discovery Filip Roudnicky** Roche 
Precise Gene Editing of Human Pluripotent Stem Cells Kris Saha** University of Wisconsin-Madison
Using human stem cells to model neocortical gyration phenotypes Ashleigh Schaffer** Department of Genetics and Genome Sciences, Case Western Reserve University
Addressing the scalability of human iPSC-derived neurons for HTS implementation and phenotypic screening BanuPriya Sridharan The Scripps Research Institute-Florida
A gut feeling about stem cell therapy for enteric neuropathies Lincon Stamp University of Melbourne
Modeling Inflammation And Fibrosis In Humans with PSC-derived Steatohepatitis Liver Organoids Takanori Takebe** Cincinnati Children’s Hospital Tokyo Medical and Dental University Yokohama City University
Accelerating cures for rare childhood diseases by building global patient communities and iPSC collections Christina Waters RARE Science Inc Global Rare Disease Program, WuXi NextCODE
Transfection using the Neon Transfection System Jackie Webb Thermo Fisher Scientific
Improvements in building in vitro pluripotent stem cell-derived disease models Erik Willems Thermo Fisher Scientific
**Keynote presenter


Presentation Speaker Affiliation
Utilization of stem cells to crack motor neuron development and degeneration Jun-An Chen** Institute of Molecular Biology Academia Sinica
Organoid technology—from adult stem cells to miniature organs Helmuth Gehart** Hubrecht Institute for Developmental Biology and Stem Cell Research
Mammalian DNA methylation landscapes and human cancers Alexander Meissner** Max Planck Institute for Molecular Genetics
Human pluripotent stem cells in understanding genetic cardiovascular disease and effects of drugs Christine Mummery** Leiden University Medical Center  
On the road to realizing tissue engineering’s transformative potential: multidisciplinary approach to accelerate bench-to-clinic transition Nina Tandon and Ben Shepherd** EpiBone Organovo  
Eliminating inherent genome editing bottlenecks in iPSCs to build physiologically relevant disease models Erik Willems** Thermo Fisher Scientific
Gibco sera—driving quality and innovation in a dynamic market Matthew Dallas and Chris Scanlon** Thermo Fisher Scientific
Industry uses of human pluripotent stem cells Stuart Chambers Amgen
Custom-tailored cardiomyocytes: Directed differentiation of human pluripotent stem cells into defined atrial and ventricular cardiomyocyte subtypes Lukas Cyganek University of Göttingen
Comparison of the teratoma assay and in vitro surrogate tests for assessment of pluripotency of human pluripotent stem cells Christian Freund Leiden University Medical Center
Directed differentiation of hematopoietic cells from human pluripotent stem cells Alessandra Giorgetti Center for Regenerative Medicine in Barcelona
Examining the negative impacts of bioflavonoids on the DNA damage response and DNA repair mechanisms in mouse embryonic stem cells Donna Goodenow University of North Carolina at Charlotte
Mechanisms for assembling and resolving naïve pluripotency Jacob Hanna Weizmann Institute of Science
Pluripotent stem cell bioprocessing platforms for cell therapy manufacturing Jahid Hasan Cell and Gene Therapy Catapult
Identification of a high titer lentiviral production alternative to facilitate regenerative medicine therapies Calley Hirsch CCRM
Building inner ear organoids from human pluripotent stem cells through directed self-assembly Karl Koehler Indiana University School of Medicine
Integrated processes for derivation, expansion and differentiation of hiPSC to blood in IPS-Spheres™ cultures Alan Lam Bioprocessing Technology Institute (BTI) of Singapore
New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells Andrew Laslett Commonwealth Industrial and Scientific Research Organisation or CSIRO
Genomic profiling reveals novel PAX7 targets CD54, integrin α9β1 and SDC2, as markers for isolation of human ES/iPS cell-derived muscle progenitors Alessandro Magli University of Minnesota
Pluripotent stem cells to explore mechanisms and treatments of neuromuscular diseases Cécile Martinat I-Stem French Stem Cell Society
iPSC-derived neural cells for drug discovery of mitochondrial brain diseases   Alessandro Prigione Max Delbrueck Center for Molecular Medicine (MDC)
New insights about Zika virus infection using iPS cells   Stevens Rehen D'Or Institute for Research and Education (IDOR) & Institute of Biomedical Sciences, Federal University of Rio de Janeiro  
Pancreatic progenitors: from the organ to the plate Meritxell Rovira Center for Regenerative Medicine in Barcelona
Braingineering’s human midbrain organoids as novel model for neurodegenerative diseases Jens Christian Schwamborn Braingineering Technologies SARL
Patient-specific hiPSCs for understanding diabetes disease mechanisms   Adrian Kee Keong Teo IMCB, A*STAR SBS and LKC Medicine, NUS Medicine
Preparing for what’s next – keys to a successful career search Sarah Gibson Thermo Fisher Scientific
How to do an elevator pitch that will win you friends, admirers and maybe even funding Kevin McCormack California Institute for Regenerative Medicine
Journal publishing tools that make your research stand out Rebecca Shumbata Mary Ann Liebert, Inc. Publishers
How to get the most out of LinkedIn Ania Wronski Thermo Fisher Scientific
Physiological oxygen: historical and molecular perspective for stem cell culture Mary Kay Bates Thermo Fisher Scientific
New viral and non-viral platforms for T-cell engineering Xavier de Mollerat du Jeu Thermo Fisher Scientific
New Gibco B-27 Plus Neuronal Culture System—next generation media  for superior  neuronal survival and functionality Navjot Kaur Thermo Fisher Scientific
New tools for improved CRISPR gene-editing in stem cells James Kehler Thermo Fisher Scientific
Highly efficient stem cell engineering via Cas9 protein transfection Xiquan Liang Thermo Fisher Scientific
Comprehensive characterization of pluripotent stem cells Suman Pradhan Thermo Fisher Scientific
**Keynote presenter


Presentation Speaker Affiliation
Genetic variability of ps-iPSC and related blood and fibroblasts—somatic mutations Silke Rickert-Sperling** Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine
Charité - Universitätsmedizin Berlin
Molecular elucidation and engineering of stem cell fate decisions David Schaffer** University of California, Berkeley
Using patient-derived iPSCs to model and treat inherited retinal degenerative blindness Budd Tucker** University of Iowa Carver College of Medicine
Optimization of your PSCs workflow Jing He Thermo Fisher Scientific
Initiatives to advance stem cell science and medicine at California’s $3 billion stem cell agency Stephen Lin California Institute for Regenerative Medicine
Partnering to advance regenerative medicine and cellular therapies Morrie Ruffin
Michael Werner
Adjuvant Partners
Holland & Knight
Evolving your media system for modern stem cell applications Rhonda Newman Thermo Fisher Scientific
From bench to BLA—a review of common regulatory questions Joyce Frey-Vasconcells
Michael Mendicino
Kelli Tanzella
Frey-Vasconcells Consulting, LLC
Hybrid Concepts International
Thermo Fisher Scientific
Precise generation of desired human cell-types from embryonic stem cells Lay Teng Ang Genome Institute of Singapore
Derivation of a spectrum of regional motor neuron phenotypes for hindbrain and spinal cord regenerative medicine Randolph Ashton University of Wisconsin Madison
Directed differentiation of induced pluripotent stem cells to hepatic stellate cells Pau Sancho Bru Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS)
Elucidating the physiological function of cellular PrPC using human iPS cell Vijay Chandrasekar Universitat Zurich
‘HipSci' and the ‘Stem cell hotel’: innovative platforms for collaborative phenotyping Davide Danovi King's College London
Disease modelling in pluripotent stem cell-derived cardiomyocytes Chris Denning University of Nottingham
Human pluripotent stem cells for the study of enteric neuropathies Faranak Fattahi Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine
Transitioning to the clinic from proof of concept research: Challenges associated with converting research materials and methods to a clinical grade product. Ben Fryer University of Washington School of Medicine
Human PSC-based disease modeling to study X-linked dystonia-parkinsonism William Hendriks Harvard Medical School
Use of stem cell models to assess genetic change underlying neurodevelopmental disorders Lachlan Jolly The University of Adelaide
Building embryonic lineages Leo Kurian CECAD - Cluster of Excellence, Institute for Neurophysiology & Center for Molecular Medicine (CMMC), University of Cologne
Human umbilical cord mesenchymal cells and the treatment of bronchopulmonary dysplasia Willie Lin Meridigen Biotech Co., Ltd.
Stem cells for regeneration and rescue Jeanne Loring The Scripps Research Institute
First allogeneic mesenchymal stromal cell product approved in India for Buerger’s disease—an unmet medical need Anish Sen Majumdar Stempeutics Research
Transplanted human stem cell-derived interneuron precursors mitigate mouse bladder dysfunction and central neuropathic pain after spinal cord injury Cory Nicholas Neurona Therapeutics
University of California, San Francisco
Exploring new avenues for cataract treatment using human pluripotent stem cells Michael O’Connor Western Sydney University
University of Sydney,
Challenge toward clinical trial for spinal cord injury using iPS cell Hideyuki Okano Keio University School of Medicine
Brain Science Institute RIKEN
Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling. Alice Pébay University of Melbourne
From urine to the study of metabolic disease—A patient-driven strategy to decipher PCSK9 roles and functions Karim Si-Tayeb l’institut du thorax INSERM
From millions to billions to trillions – translating your cell discovery into a cell product Nick Timmins CCRM, Canada
Regulation of autologous cell clinical interventions Bernie Tuch NSW Stem Cell Network
Immunomodulation and immunogenicity of human MSC-like cells: What did we learn from in vitro and in vivo studies? Hans-Dieter Volk Charité-Universitätsmedizin Berlin
Translating pluripotent stem cell therapies for focal brain disorders Dustin Wakeman RxGen, Inc.
Improved differentiation of human pluripotent stem cell-derived neurons through reduction of progenitor proliferation: impact on downstream applications David Kuninger Thermo Fisher Scientific
Analyzing stem cell populations using flow cytometry Jolene Bradford Thermo Fisher Scientific
Techniques and recommendations for colony selection and passage of iPSC Chad MacArthur Thermo Fisher Scientific
The matrix equation—solving for the best PSC culture goals Rhonda Newman Thermo Fisher Scientific
iPSC generation and validation: Ensuring the best materials for downstream applications Rene Quintanilla Thermo Fisher Scientific
Delivery solutions for robust CRISPR-based genomic editing in stem cells for disease model generation    Nektaria Andronikou Thermo Fisher Scientific
**Keynote presenter


Presentation Speaker Affiliation
Genome editing and stem cell engineering for disease modeling Jon Chesnut** Thermo Fisher Scientific
Probing disease mechanisms in ALS and ion-channel epilepsy using iPSCs, reprogramming and optogenetic approaches  Evangelos Kiskinis** Northwestern University
Biomaterials for assembly of stem cell-derived human tissues William Murphy** University of Wisconsin
Epigenetic regulation in stem cells and reprogramming Alexander Meissner Harvard University
Harvard Stem Cell Institute
Standardizing stem cell research Alexander Meisner Ernest Wolvetang Tennielle Ludwig  
Differentiation of midbrain floor plate progenitors and dopaminergic neurons from human pluripotent stem cells Soojung Shin Thermo Fisher Scientific
Essential 8 Flex: Eliminating daily feeding in feeder-free, xeno-free PSC culture system Matthew Dallas Thermo Fisher Scientific
Antibodies for stem cell research Kara Machledit Thermo Fisher Scientific
Highly efficient genome editing and cell engineering in stem cells using CRISPR/Cas9 Namritha Ravinder Shantanu Kumar Thermo Fisher Scientific
Improved T cell function and in vivo engraftment of CAR-T cells expanded ex vivo with CTS Immune Cell SR Angel Varela Rohena Thermo Fisher Scientific
Pluripotent stem cell characterization methods Deborah Tieberg Thermo Fisher Scientific
Pluripotent stem cell culture systems: Identification of appropriate medium, matrix and passaging reagent Rhonda Newman Thermo Fisher Scientific
PSCs to cardiomyocytes in three steps Alex Hannay Thermo Fisher Scientific
Thermo Fisher Scientific’s cell therapy capabilities Brian Newsom Thermo Fisher Scientific
Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling Alice Pébay   University of Melbourne
HOXA gene expression defines definitive fetal hematopoietic cells differentiated from human embryonic stem cells Andrew Elefanty Murdoch Children’s Research Institute
Muscle stem cells harboring basal levels of pluripotency genes are amenable to pluripotent conversion without using reprogramming factors or small molecules Bipasha Bose Yenepoya University
The use of modified mRNA to enhance the generation of induced neural precursor cells from adult human fibroblasts Bronwen Connor University of Auckland
Functional dissection of disease-associated chromosomal deletions with human iPSCs Eirini Papapetrou Icahn School of Medicine at Mount Sinai
Human oocyte as source of information to study cell pluripotency and reprogramming Elena González Muñoz Centro Andaluz de Nanomedicina y Biotecnología (BIONAND)
Standardized generation of patient-specific iPSC lines and scalable production of PSC-derived cardiomyocytes Emily Titus CCRM, Canada
In vitro quantification of the terminal differentiation potential of pluripotent stem cells Ernst Wolvetang University of Queensland
A novel  PSC-based myogenic platform to explore treatment strategies for muscle diseases Jérôme Chal Harvard Medical School  
The laminin protein family—key to stem cell culture Jesper Ericsson BioLamina
Variability of cardiomyocyte differentiation among human pluripotent stem cells: A practical screening approach Katherine Santostefano University of Florida Center for Cellular Reprogramming
Modeling predisposition to schizophrenia using hiPSCs Kristen Brennad Icahn School of Medicine at Mount Sinai
Dental pulp of the third molar: a new source of pluripotent-like stem cells Maher Atari Universitat Internacional de Catalunya
Generation of induced pluripotent stem (iPS) cell-derived cardiomyocytes for disease modeling and drug discovery Nirupama Pike Stem Cell Theranostics
Efficient generation of footprint-free patient-specific iPS cells and the application for drug screening Noemi Fusaki Keio University School of Medicine
Scalable xeno-free culture system for human induced pluripotent stem cells Tiago Fernandes Institute for Bioengineering and Biosciences
Tissue engineering of hiPSC for endothelial cell regeneration and cardiac repair Ye Lei National Heart Centre Singapore
Toward large-scale functional genomic studies through the automation of induced pluripotent stem cell derivation, expansion and differentiation Daniel Paull New York Stem Cell Foundation
Modeling eye diseases using human adult retinal pigment epithelium stem cells Timothy Blenkinsop Icahn School of Medicine at Mount Sinai
Combined stem cell transplantation and gene therapy on the regeneration of corticospinal axons after spinal cord injury Stuart Hodgetts University of Western Australia  
**Keynote presenter


Presentation Speaker Affiliation
The future of pluripotent stem cell banking Jonathan Loh Yuin-Han A*STAR Institute of Molecular and Cell Biology
Utility of gene expression signatures for the characterization of cellular identity Alexander Meissner Harvard Stem Cell Institute
Reprogramming cells to study mental disorders Stevens Rehen Institute of Biomedical Sciences, Federal University of Rio de Janeiro and D’Or Institute for Research and Education
Molecular engineering of biomaterial platforms for scalable stem cell manufacturing David Schaffer University of California at Berkeley
Using iPS cell technology to model human neurodegenerative diseases Angel Raya Center for Regenerative Medicine in Barcelona (CMRB)
Pluripotent stem cells to model human brain development Chris Fasano Neural Stem Cell Institute
Scalable production of human stem/progenitor cells in bioreactor systems Claudia Lobato da Silva Stem Cell Bioengineering and Regenerative Medicine Laboratory, Instituto Superior Técnico, Universidade de Lisboa
Deriving functional hepatocytes from pluripotent stem cells David Hay MRC Centre for Regenerative Medicine
Hematopoietic disease modeling using iPSCs Deborah French The Children's Hospital of Philadelphia
Development of chemically defined cell culture for human pluripotent stem cells Guokai Chen University of Macau, China
Culture adaptation of pluripotent stem cells: an in vitro model for oncogenesis Ivana Barbaric University of Sheffield
iPSCs for modeling disease in Africa Janine Scholefield CSIR Biosciences
Reversibility of the cellular aging physiology through an iPSC state : a new paradigm for human cell rejuvenation Jean-Marc Lemaitre Institute of Regenerative Medicine and Biotherapies, INSERM, Stem Cell Core Facility SAFE-iPSC
Derivation and function of clinical-grade human ESCs in Parkinson's disease monkey models Jie Hao Chinese Academy of Sciences
Knock-in gene correction in pyruvate kinase deficiency patient–derived iPSC, the most common metabolic erythroid disease Jose Carlos Segovia CIEMAT/CIBERER
Developing autologous cell therapy for macular degeneration using IPS cell–derived RPE tissue: a model for public-private partnership Kapil Bharti National Eye Institute, National Institutes of Health
Reprogramming somatic cells using the Sendai virus technology Laurence Daheron Harvard Stem Cell Institute
Mechanisms of reprogramming: applying lessons from mouse models to improve the efficiency of an iPSC core facility Laurent David Medical School of University of Nantes
Induced pluripotent stem cells: time for standards Mathilde Girard I-Stem
Pluripotency factors and cell lineage specification Michael Puceat French National Institute of Health and Medical  Research, INSERM
The challenges and possible solutions for transferring cell therapy from the bench to the industry, while assuring high quality and manufacturing efficiency Ohad Karnieli Pluristem Therapeutics Inc
SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells Pedro Real GENYO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government
Cellular immune therapy for virus-associated human malignancies and post-transplant infectious complications Rajiv Khanna QIMR Centre for Immunotherapy and Vaccine Development
QIMR Berghofer Medical Research Institute
Developing a human embryonic stem cell based therapy for multiple sclerosis Ren-He Xu University of Macau
Developing a human ES cell derived dopamine neuron source for cell therapy in Parkinson's disease—from academic to translational research Stefan Irion MSKCC
Chromatin modifiers in reprogramming Tamer Onder Koç University
iPSC reprogramming from human blood using Sendai virus mediated gene transfer Wenli Yang University of Pennsylvania
Use of pluripotent stem cells to model premature aging syndromes Xavier Nissan CECS, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases
Transcriptome profiling and stem cell-based therapies Yi Sun UCLA Institute for Stem Cell Biology and Medicine
Stage-specific grafting of hESC-derived midbrain dopamine neurons Yosif Ganat MSKCC
Pharmacological modulation of cell fates Yu Wang Chinese Academy of Sciences
Personalized disease model in dish -  Starting with Parkinson’s Disease Jing He
Bo Peng
Thermo Fisher Scientific
Hands-free stem cell research: services to save you time Carolyn Pettersson Thermo Fisher Scientific
Cell therapy logistics—beyond the basics Dan O’Donnell Thermo Fisher Scientific
Trends and considerations for cell therapy development Eric Roos Thermo Fisher Scientific
Considerations for creating a disease model for Parkinson's disease using stem cells Kurt Vogel Thermo Fisher Scientific
Efficient cell specific differentiation systems for iPSC Mohan Vemuri Thermo Fisher Scientific
Antibody based tools and protocols for characterization of pluripotent stem cells Nirupama Pike Thermo Fisher Scientific
Considerations for the culture of pluripotent stem cells Jennifer Crean Thermo Fisher Scientific
Differentiate pluripotent stem cells to contracting cardiomyocytes in 3 easy steps Alex Hannay Thermo Fisher Scientific
Eliminate serum to gain control of your T cell research Sandra Kuligowski Thermo Fisher Scientific
Rapid induction of neural stem cells without the need for EB formation Alex Hannay Thermo Fisher Scientific
Score! A gene expression profile for your iPS lines Deborah Tieberg Thermo Fisher Scientific


Presentation Speaker Affiliation
Genome editing to generate human cellular disease models Chad Cowan** Harvard University
Pluripotency and differentiation Alexander Meissner** Harvard University
Reprogramming human hematopoietic cells for regenerative medicine Elias Zambidis** Johns Hopkins University School of Medicine
Human pluripotent stem cell-derived dopaminergic neurons for screening Xianmin Zeng Buck Institute for Research and Aging; Xcell Science, Inc.
Transcriptional analysis during reprogramming at the single cell level. Jose Polo** Monash University
Hematopoietic differentiation of human pluripotent stem cells Junfeng Ji Zhejiang University
iPSC-dervied NSCs from Life Technologies Gibco  Neural Induction Medium Michael Edel** Universitat de Barcelona
Using iPS cell technology to model human neurodegenerative diseases Angel Raya** IBEC, Barcelona
iPSCs for modeling disease in Africa Janine Scholefield** Councel for Scientific and Industrial Research (CSIR)
Parkinson’s Part I: Life Technologies and the Parkinson’s Institute collaborate to understand the molecular basis for Parkinson’s disease Roland Leathers Thermo Fisher Scientific
Parkinson’s Part II: Generation of induced pluripotent stem cells from Parkinson’s disease fibroblasts Connie Lebakken Thermo Fisher Scientific
Parkinson’s Part III: Generation and characterization of neural stem cells from Parkinson’s disease donor-derived iPSCs Kun Bi Thermo Fisher Scientific
Parkinson’s Part IV: Genome Editing of Parkinson’s Disease iPSCs Using GeneArt Precision TAL Technology Spencer Hermanson Thermo Fisher Scientific
Considerations for culturing neural stem cells Yiping Ya, Soojung Shin Thermo Fisher Scientific
Considerations for culturing mesenchymal stem cells Shayne Boucher Thermo Fisher Scientific
Considerations for culturing pluripotent stem cells Marian Piekarczyk Thermo Fisher Scientific
Considerations for reprogramming pluripotent stem cells Chad MacArthur Thermo Fisher Scientific
Considerations for characterizing pluripotent stem cells Rene Quintanilla Thermo Fisher Scientific
CytoTune-iPS Sendai 2.0 Reprogramming Kit Jennifer Crean Thermo Fisher Scientific
TaqMan hPSC Scorecard Panel and data analysis software Deborah Tieberg Thermo Fisher Scientific
Essential 8 media and vitronectin James Lovgren Thermo Fisher Scientific
Cell Model Services for stem cell research Carolyn Pettersson Thermo Fisher Scientific
Products and services for neural differentiation Alex Hannay Thermo Fisher Scientific
Genome editing tools—GeneArt TALs & CRISPRs Farzad Haerizadeh Thermo Fisher Scientific
**Keynote presenter
*Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of products presented by third parties during this event.  Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results.  Parties presenting images, text, and materials represent they have the right to do so.